Peptidomimetic Inhibitors of Herpes Simplex Virus Ribonucleotide Reductase with Improved in Vivo Antiviral Activity

We have been investigating the potential of a new class of antiviral compounds. These peptidomimetic derivatives prevent association of the two subunits of herpes simplex virus (HSV) ribonucleotide reductase (RR), an enzyme necessary for efficient replication of viral DNA. The compounds disclosed in...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 39; no. 21; pp. 4173 - 4180
Main Authors Moss, Neil, Beaulieu, Pierre, Duceppe, Jean-Simon, Ferland, Jean-Marie, Garneau, Michel, Gauthier, Jean, Ghiro, Elise, Goulet, Sylvie, Guse, Ingrid, Jaramillo, Jorge, Llinas-Brunet, Montse, Malenfant, Éric, Plante, Raymond, Poirier, Martin, Soucy, Francois, Wernic, Dominik, Yoakim, Christiane, Déziel, Robert
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 11.10.1996
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We have been investigating the potential of a new class of antiviral compounds. These peptidomimetic derivatives prevent association of the two subunits of herpes simplex virus (HSV) ribonucleotide reductase (RR), an enzyme necessary for efficient replication of viral DNA. The compounds disclosed in this paper build on our previously published work. Structure−activity studies reveal beneficial modifications that result in improved antiviral potency in cell culture in a murine ocular model of HSV-induced keratitis. These modifications include a stereochemically defined (2,6-dimethylcyclohexyl)amino N-terminus, two ketomethylene amide bond isosteres, and a (1-ethylneopentyl)amino C-terminus. These three modifications led to the preparation of BILD 1351, our most potent antiherpetic agent containing a ureido N-terminus. Incorporation of the C-terminal modification into our inhibitor series based on a (phenylpropionyl)valine N-terminus provided BILD 1357, a significantly more potent antiviral compound than our previously published best compound, BILD 1263.
Bibliography:ark:/67375/TPS-DXGN2P60-R
Abstract published in Advance ACS Abstracts, September 1, 1996.
istex:4080E35BF2E26A2272297F56832A9DA123337395
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-2623
1520-4804
DOI:10.1021/jm960324r